Therapy Stock Review: Outstanding 10.96% Weekly Gain $BIIB, $URGN, $ALLO
Thriving in Therapy: A Deeper Look into the Biotech and Pharmaceutical Theme
Overview of the Therapy Theme
Theme Therapy +10.96% - 1W change
Swing trader: Long-Short Equity Strategy (TA&FA) Annualized Return + 64% and Swing trader: High Capitalization (TA) Annualized Return + 7%
As the world grapples with various health challenges, the need for innovative therapeutic solutions cannot be overstated. In the financial market, the Therapy theme represents an intriguing investment opportunity. This theme focuses on biotech and pharmaceutical companies that discover, develop, manufacture, and deliver therapies for treating various diseases and disorders. The industry is part of the overall healthcare field but has a specific focus on the development of treatments to cure or prevent diseases.
This theme includes tickers such as $ACRS, $ALLO, $ALNY, $ARVN, $BIIB, $BPMC, $EVLO, $INMB, $KRYS, $LIVN, $OCUL, $URGN, $USPH, and $VKTX. These companies are diverse in their operations but united by their commitment to developing and delivering life-saving therapies.
Market Capitalization Analysis
These therapy-themed companies boast a collective average market capitalization of $5.8B, with individual valuations ranging from $153.8M to a whopping $39.1B. Leading the pack is Biogen ($BIIB) with the highest valuation of $39.1B, while Immune Bio Inc. ($INMB) trails with the smallest market cap at $153.8M.
A Peek into Performance: Allogene Therapeutics ($ALLO), UroGen Pharma ($URGN), and Biogen ($BIIB)
Allogene Therapeutics ($ALLO)
Allogene Therapeutics has demonstrated some volatility in its performance. For instance, the company experienced a notable downtrend with a -6.62% decrease on July 25, 2023, and a -8.49% fall on July 15, 2023. However, the company also showed resilience with a +9.61% jump on July 7, 2023, indicating an uptrend reversal. This fluctuation in performance demonstrates the dynamic nature of the biotech industry.
UroGen Pharma ($URGN)
UroGen Pharma, on the other hand, has been a high flyer in the Therapy theme, exhibiting the highest price growth at 129.64%. This significant growth reflects the company's innovative approach to developing and commercializing therapies designed to change the standard of care for urological pathologies.
Biogen ($BIIB)
Biogen, the heavyweight in this theme, demonstrates why it commands such a massive market capitalization. With a valuation of $39.1B, the company continues to be a major player in the industry, providing a wide array of therapies for diseases such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, among others.
Volume Fluctuation Analysis
The average weekly volume growth across all stocks in the group stands at 95.5%. Allogene Therapeutics ($ALLO) experienced a record-breaking daily growth of 1,009% of the 65-Day Volume Moving Average on June 24, 2023. On May 26, 2023, US Physical Therapy ($USPH) had a similar record-breaking daily growth of 1,369% of the 65-Day Volume Moving Average. Krystal Biotech ($KRYS) also experienced a significant two-day consecutive volume increase, resulting in a daily growth of 178% of the 65-Day Volume Moving Average on May 25, 2023. These volume fluctuations provide an insightful look into investor interest and trading activity within the Therapy theme.
Fundamental Analysis Ratings
Fundamental analysis ratings provide another valuable perspective on the health and potential of companies within this theme. On average, companies in this theme have a Valuation Rating of 72, P/E Growth Rating of 88, a Price Growth Rating of 51, an SMR Rating of 91, and a Profit Risk Rating of 83. The Seasonality Score stands at 15. These scores indicate the overall health and potential for growth of these companies, offering another piece of the investment decision puzzle.
The Therapy theme offers a myriad of opportunities for investors who are passionate about healthcare and the development of novel therapeutic treatments. The performance of the companies under this theme not only shows their potential for growth but also the crucial role they play in improving global health outcomes.
BIIB in +3.71% Uptrend, rising for three consecutive days on May 06, 2024
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BIIB advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on April 26, 2024. You may want to consider a long position or call options on BIIB as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BIIB just turned positive on April 24, 2024. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
BIIB moved above its 50-day moving average on April 29, 2024 date and that indicates a change from a downward trend to an upward trend.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BIIB broke above its upper Bollinger Band on April 29, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BIIB entered a downward trend on April 29, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BIIB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.110) is normal, around the industry mean (5.632). P/E Ratio (26.955) is within average values for comparable stocks, (48.974). BIIB's Projected Growth (PEG Ratio) (8.807) is slightly higher than the industry average of (3.004). Dividend Yield (0.000) settles around the average of (0.164) among similar stocks. P/S Ratio (3.181) is also within normal values, averaging (3.643).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders
Industry PharmaceuticalsMajor